Secondary Prevention of Venous Thrombo Embolism (VTE).
- Registration Number
- NCT00329238
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous thromboembolism in patients who have been successfully treated with standard doses of an approved anticoagulant for three to twelve months for confirmed acute symptomatic Venous Thrombo-embolism.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2867
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Dabigatran Dabigatran Patient to receive 1 capsule containing dabigatran 150 mg twice daily plus placebo tablets for warfarin as decided by sham INR measurements Warfarin (INR of 2.0-3.0) Warfarin Patient to receive warfarin tablets to target INR 2.0-3.0 plus placebo capsules for dabigatran twice daily
- Primary Outcome Measures
Name Time Method Composite of Recurrent VTE or VTE Death at 36 Months 36 months Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE.
Composite of Recurrent VTE or VTE Death at 18 Months 18 months Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE.
- Secondary Outcome Measures
Name Time Method Deep Vein Thrombosis (DVT) at 36 Months 36 months Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation.
Composite of Recurrent VTE or All Cause Death at 36 Months 36 months Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation.
Composite of Recurrent VTE or All Cause Death at 18 Months 18 months Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation.
Deaths Related to VTE at 36 Months 36 months Deaths related to VTE (i.e. fatal PE) at 36 Months. Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way.
Deaths of All Causes at 36 Months 36 months Deaths of all causes at 36 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments.
Deaths of All Causes at 18 Months 18 months Deaths of all causes at 18 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments.
Laboratory Analysis 18 months + 30 days follow up Patients with LFT (liver function tests) increases of possible clinical significance during treatment. Increases of possible clinical significance were defined as: ≥3 x ULN (AST, ALT), ≥2 x ULN (AP), and ≥2 mg/dL (total bilirubin). Only patients with a baseline value which was not of possible clinical significance (or without any baseline value) could have a PCSA (Possible clinically significant abnormality).
Deaths Related to VTE at 18 Months 18 months Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way.
DVT at 18 Months 18 months Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation.
Number of Participants With Definite Acute Coronary Syndrome (ACS) day of first study drug intake until last day of study drug intake; from the day after last intake of study drug until trial termination All suspected ACS occurring during the trial were to be recorded on the CRF and were to be centrally adjudicated by an independent ACS/AC in a treatment-blinded manner.
Symptomatic Pulmonary Embolism (PE) at 36 Months 36 months Symptomatic pulmonary embolism (PE) at 36 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography.
Symptomatic Pulmonary Embolism (PE) at 18 Months 18 months Symptomatic pulmonary embolism (PE) at 18 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography.
Number of Participants With Bleeding Events first intake of study drug until 6 days following last intake of study drug MBE (major bleeding event) if it fulfilled at least one of the following criteria
* Fatal bleeding
* Symptomatic bleeding in a critical area or organ.
* Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells.
Minor bleeding event was any bleeding that did not fulfil any of the criteria for MBEs
CRBE (clinically relevant bleeding event) if it is a minor bleeding events which fulfilled at least one of the following criteria
* Spontaneous skin haematoma ≥25 cm2
* Spontaneous nose bleed \>5 min duration
* Macroscopic haematuria, either spontaneous or, if associated with an intervention, lasting \>24 h
* Spontaneous rectal bleeding
* Gingival bleeding \>5 min
* Bleeding leading to hospitalisation or requiring surgical treatment
* Bleeding leading to a transfusion of \<2 units of whole blood or red cells
* Any other bleeding event considered clinically relevant by the investigator
Trial Locations
- Locations (275)
1160.47.01030 Boehringer Ingelheim Investigational Site
🇺🇸Grand Forks, North Dakota, United States
1160.47.02019 Boehringer Ingelheim Investigational Site
🇨🇦Toronto, Ontario, Canada
1160.47.52030 Boehringer Ingelheim Investigational Site
🇲🇽Guadalajara, Jal., Mexico
1160.47.48007 Boehringer Ingelheim Investigational Site
🇵🇱Krakow, Poland
1160.47.35107 Boehringer Ingelheim Investigational Site
🇵🇹Covilhã, Portugal
1160.47.42106 Boehringer Ingelheim Investigational Site
🇸🇰Lucenec, Slovakia
1160.47.01044 Boehringer Ingelheim Investigational Site
🇺🇸Clearwater, Florida, United States
1160.47.01019 Boehringer Ingelheim Investigational Site
🇺🇸Augusta, Georgia, United States
1160.47.01014 Boehringer Ingelheim Investigational Site
🇺🇸Baltimore, Maryland, United States
1160.47.01052 Boehringer Ingelheim Investigational Site
🇺🇸Altoona, Pennsylvania, United States
1160.47.01035 Boehringer Ingelheim Investigational Site
🇺🇸Mobile, Alabama, United States
1160.47.01008 Boehringer Ingelheim Investigational Site
🇺🇸Decatur, Georgia, United States
1160.47.01036 Boehringer Ingelheim Investigational Site
🇺🇸Albuquerque, New Mexico, United States
1160.47.54011 Boehringer Ingelheim Investigational Site
🇦🇷Rosario, Argentina
1160.47.54013 Boehringer Ingelheim Investigational Site
🇦🇷Quilmes, Argentina
1160.47.01009 Boehringer Ingelheim Investigational Site
🇺🇸St. Louis Park, Minnesota, United States
1160.47.55010 Boehringer Ingelheim Investigational Site
🇧🇷Brasília, Brazil
1160.47.55012 Boehringer Ingelheim Investigational Site
🇧🇷pTO aLEGRE, Brazil
1160.47.61006 Boehringer Ingelheim Investigational Site
🇦🇺Windsor, Victoria, Australia
1160.47.61002 Princess Alexandra Hospital
🇦🇺Wooloongabba, Queensland, Australia
1160.47.54018 Boehringer Ingelheim Investigational Site
🇦🇷Salta, Argentina
1160.47.54012 Boehringer Ingelheim Investigational Site
🇦🇷Santa Fe, Argentina
1160.47.55017 Boehringer Ingelheim Investigational Site
🇧🇷Juvene - Paraná -, Brazil
1160.47.42004 Boehringer Ingelheim Investigational Site
🇨🇿Praha 2, Czech Republic
1160.47.3308A Boehringer Ingelheim Investigational Site
🇫🇷Vandoeuvre les Nancy, France
1160.47.3303B Boehringer Ingelheim Investigational Site
🇫🇷St Etienne Cedex 2, France
1160.47.42011 Boehringer Ingelheim Investigational Site
🇨🇿Hranice, Czech Republic
1160.47.35801 Boehringer Ingelheim Investigational Site
🇫🇮Helsinki, Finland
1160.47.49003 Boehringer Ingelheim Investigational Site
🇩🇪Köln, Germany
1160.47.36006 Boehringer Ingelheim Investigational Site
🇭🇺Budapest, Hungary
1160.47.3301B Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.47.3301E Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.47.35804 Boehringer Ingelheim Investigational Site
🇫🇮Espoo, Finland
1160.47.42015 Boehringer Ingelheim Investigational Site
🇨🇿Novy Jicin, Czech Republic
1160.47.35803 Boehringer Ingelheim Investigational Site
🇫🇮Tampere, Finland
1160.47.3301F Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.47.3301C Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.47.3301D Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.47.3303A Boehringer Ingelheim Investigational Site
🇫🇷St Etienne Cedex 2, France
1160.47.49017 Boehringer Ingelheim Investigational Site
🇩🇪Dresden, Germany
1160.47.42012 Boehringer Ingelheim Investigational Site
🇨🇿Liberec, Czech Republic
1160.47.35802 Boehringer Ingelheim Investigational Site
🇫🇮Jyväskylä, Finland
1160.47.35805 Boehringer Ingelheim Investigational Site
🇫🇮Kuopio, Finland
1160.47.30006 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1160.47.49007 Boehringer Ingelheim Investigational Site
🇩🇪München, Germany
1160.47.3303D Boehringer Ingelheim Investigational Site
🇫🇷St Etienne Cedex 2, France
1160.47.91005 Boehringer Ingelheim Investigational Site
🇮🇳Pune, India
1160.47.97208 Boehringer Ingelheim Investigational Site
🇮🇱Rehovot, Israel
1160.47.97204 Boehringer Ingelheim Investigational Site
🇮🇱Tel Hashomer, Israel
1160.47.3301H Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.47.64003 Boehringer Ingelheim Investigational Site
🇳🇿Grafton, New Zealand
1160.47.3301I Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.47.49009 Boehringer Ingelheim Investigational Site
🇩🇪Püttlingen, Germany
1160.47.49018 Boehringer Ingelheim Investigational Site
🇩🇪Dresden, Germany
1160.47.91002 Boehringer Ingelheim Investigational Site
🇮🇳Ahmedabad, India
1160.47.31010 Boehringer Ingelheim Investigational Site
🇳🇱Den Bosch, Netherlands
1160.47.39004 Boehringer Ingelheim Investigational Site
🇮🇹Cremona, Italy
1160.47.36007 Boehringer Ingelheim Investigational Site
🇭🇺Budapest, Hungary
1160.47.39005 Boehringer Ingelheim Investigational Site
🇮🇹Vittorio Veneto, Italy
1160.47.36010 Boehringer Ingelheim Investigational Site
🇭🇺Székesfehérvár, Hungary
1160.47.64002 Boehringer Ingelheim Investigational Site
🇳🇿Otahuhu, New Zealand
1160.47.91006 Boehringer Ingelheim Investigational Site
🇮🇳new Delhi, India
1160.47.31004 Boehringer Ingelheim Investigational Site
🇳🇱Rotterdam, Netherlands
1160.47.39006 Boehringer Ingelheim Investigational Site
🇮🇹Genova, Italy
1160.47.97201 Boehringer Ingelheim Investigational Site
🇮🇱Zerifin, Israel
1160.47.07021 Boehringer Ingelheim Investigational Site
🇷🇺Chelyabinsk, Russian Federation
1160.47.91012 Boehringer Ingelheim Investigational Site
🇮🇳Chennai, India
1160.47.39003 Boehringer Ingelheim Investigational Site
🇮🇹Bologna, Italy
1160.47.36011 Boehringer Ingelheim Investigational Site
🇭🇺Szombathely, Hungary
1160.47.97202 Boehringer Ingelheim Investigational Site
🇮🇱Afula, Israel
1160.47.97206 Boehringer Ingelheim Investigational Site
🇮🇱Petach Tikva, Israel
1160.47.97205 Boehringer Ingelheim Investigational Site
🇮🇱Kfar Saba, Israel
1160.47.91017 Boehringer Ingelheim Investigational Site
🇮🇳Chennai, India
1160.47.31014 Boehringer Ingelheim Investigational Site
🇳🇱Heerlen, Netherlands
1160.47.31009 Boehringer Ingelheim Investigational Site
🇳🇱Rotterdam, Netherlands
1160.47.39008 Boehringer Ingelheim Investigational Site
🇮🇹Milano, Italy
1160.47.39007 Boehringer Ingelheim Investigational Site
🇮🇹Reggio Emilia, Italy
1160.47.97203 Boehringer Ingelheim Investigational Site
🇮🇱Holon, Israel
1160.47.07024 Boehringer Ingelheim Investigational Site
🇷🇺Rostov-na-Donu, Russian Federation
1160.47.64001 Boehringer Ingelheim Investigational Site
🇳🇿Takapuna Auckland 9, New Zealand
1160.47.97210 Boehringer Ingelheim Investigational Site
🇮🇱Tel Aviv, Israel
1160.47.35104 Boehringer Ingelheim Investigational Site
🇵🇹Almada, Portugal
1160.47.27001 Boehringer Ingelheim Investigational Site
🇿🇦Johannesburg, South Africa
1160.47.27002 Boehringer Ingelheim Investigational Site
🇿🇦Johannesburg, South Africa
1160.47.34006 Boehringer Ingelheim Investigational Site
🇪🇸Alicante, Spain
1160.47.42102 Boehringer Ingelheim Investigational Site
🇸🇰Nitra, Slovakia
1160.47.38002 Boehringer Ingelheim Investigational Site
🇺🇦Kharkov, Ukraine
1160.47.46008 Boehringer Ingelheim Investigational Site
🇸🇪Stockholm, Sweden
1160.47.90004 Boehringer Ingelheim Investigational Site
🇹🇷Ankara, Turkey
1160.47.90006 Boehringer Ingelheim Investigational Site
🇹🇷Izmir, Turkey
1160.47.34011 Boehringer Ingelheim Investigational Site
🇪🇸Valencia, Spain
1160.47.42103 Boehringer Ingelheim Investigational Site
🇸🇰Nove Zamky, Slovakia
1160.47.34001 Boehringer Ingelheim Investigational Site
🇪🇸Barcelona, Spain
1160.47.27006 Boehringer Ingelheim Investigational Site
🇿🇦Johannesburg, South Africa
1160.47.46003 Boehringer Ingelheim Investigational Site
🇸🇪Uppsala, Sweden
1160.47.90002 Boehringer Ingelheim Investigational Site
🇹🇷Istanbul, Turkey
1160.47.27005 Boehringer Ingelheim Investigational Site
🇿🇦Roodepoort, South Africa
1160.47.38003 Boehringer Ingelheim Investigational Site
🇺🇦Zaporozhye, Ukraine
1160.47.46007 Boehringer Ingelheim Investigational Site
🇸🇪Stockholm, Sweden
1160.47.90003 Boehringer Ingelheim Investigational Site
🇹🇷Ankara, Turkey
1160.47.34007 Boehringer Ingelheim Investigational Site
🇪🇸Cartagena. Murcia, Spain
1160.47.34003 Boehringer Ingelheim Investigational Site
🇪🇸Cuenca, Spain
1160.47.34012 Boehringer Ingelheim Investigational Site
🇪🇸Badalona (Barcelona), Spain
1160.47.38005 Boehringer Ingelheim Investigational Site
🇺🇦Vinnitsa, Ukraine
1160.47.46005 Boehringer Ingelheim Investigational Site
🇸🇪Sundsvall, Sweden
1160.47.90001 Boehringer Ingelheim Investigational Site
🇹🇷Istanbul, Turkey
1160.47.38006 Boehringer Ingelheim Investigational Site
🇺🇦Kiev, Ukraine
1160.47.32002 Boehringer Ingelheim Investigational Site
🇧🇪Bruxelles, Belgium
1160.47.32005 Boehringer Ingelheim Investigational Site
🇧🇪Leuven, Belgium
1160.47.32004 Boehringer Ingelheim Investigational Site
🇧🇪Liège, Belgium
1160.47.31001 Boehringer Ingelheim Investigational Site
🇳🇱Amersfoort, Netherlands
1160.47.31006 Boehringer Ingelheim Investigational Site
🇳🇱Amsterdam, Netherlands
1160.47.31005 Boehringer Ingelheim Investigational Site
🇳🇱Maastricht, Netherlands
1160.47.30001 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1160.47.61005 Boehringer Ingelheim Investigational Site
🇦🇺Perth, Western Australia, Australia
1160.47.86014 Boehringer Ingelheim Investigational Site
🇨🇳Chengdu, China
1160.47.86012 Boehringer Ingelheim Investigational Site
🇨🇳Guangzhou, China
1160.47.86009 Boehringer Ingelheim Investigational Site
🇨🇳Hangzhou, China
1160.47.86010 Boehringer Ingelheim Investigational Site
🇨🇳Hangzhou, China
1160.47.86013 Boehringer Ingelheim Investigational Site
🇨🇳Nanjing, China
1160.47.86002 Boehringer Ingelheim Investigational Site
🇨🇳Shanghai, China
1160.47.86004 Boehringer Ingelheim Investigational Site
🇨🇳Shanghai, China
1160.47.86006 Boehringer Ingelheim Investigational Site
🇨🇳Shanghai, China
1160.47.86007 Boehringer Ingelheim Investigational Site
🇨🇳Shanghai, China
1160.47.86016 Boehringer Ingelheim Investigational Site
🇨🇳Shanghai, China
1160.47.86011 Boehringer Ingelheim Investigational Site
🇨🇳Shijiazhuang, China
1160.47.45008 Boehringer Ingelheim Investigational Site
🇩🇰Esbjerg, Denmark
1160.47.45009 Boehringer Ingelheim Investigational Site
🇩🇰Holbæk, Denmark
1160.47.45002 Boehringer Ingelheim Investigational Site
🇩🇰Kolding, Denmark
1160.47.45007 Boehringer Ingelheim Investigational Site
🇩🇰København S, Denmark
1160.47.45006 Boehringer Ingelheim Investigational Site
🇩🇰Slagelse, Denmark
1160.47.3303C Boehringer Ingelheim Investigational Site
🇫🇷St Etienne Cedex 2, France
1160.47.01023 Boehringer Ingelheim Investigational Site
🇺🇸Detroit, Michigan, United States
1160.47.44006 Boehringer Ingelheim Investigational Site
🇬🇧Newcastle upon Tyne, United Kingdom
1160.47.27007
🇿🇦Pretoria, South Africa
1160.47.34009 Boehringer Ingelheim Investigational Site
🇪🇸Madrid, Spain
1160.47.07010 Boehringer Ingelheim Investigational Site
🇷🇺Novosibirsk, Russian Federation
1160.47.01056 Boehringer Ingelheim Investigational Site
🇺🇸Hartford, Connecticut, United States
1160.47.01018 Boehringer Ingelheim Investigational Site
🇺🇸Roxbury Crossing, Massachusetts, United States
1160.47.01031 Boehringer Ingelheim Investigational Site
🇺🇸Lebanon, New Hampshire, United States
1160.47.01027 Boehringer Ingelheim Investigational Site
🇺🇸Chapel Hill, North Carolina, United States
1160.47.01013 Boehringer Ingelheim Investigational Site
🇺🇸Toledo, Ohio, United States
1160.47.01017 Boehringer Ingelheim Investigational Site
🇺🇸Richmond, Virginia, United States
1160.47.54017 Boehringer Ingelheim Investigational Site
🇦🇷Adrogué, Argentina
1160.47.01055 Boehringer Ingelheim Investigational Site
🇺🇸Summerville, South Carolina, United States
1160.47.54003 Boehringer Ingelheim Investigational Site
🇦🇷Capital Federal, Argentina
1160.47.54015 Boehringer Ingelheim Investigational Site
🇦🇷Bahía Blanca, Argentina
1160.47.54001 Boehringer Ingelheim Investigational Site
🇦🇷Capital Federal, Argentina
1160.47.54005 Boehringer Ingelheim Investigational Site
🇦🇷Capital Federal, Argentina
1160.47.54006 Boehringer Ingelheim Investigational Site
🇦🇷Capital Federal, Argentina
1160.47.54007 Boehringer Ingelheim Investigational Site
🇦🇷Capital Federal, Argentina
1160.47.54010 Boehringer Ingelheim Investigational Site
🇦🇷Capital Federal, Argentina
1160.47.54016 Boehringer Ingelheim Investigational Site
🇦🇷La Plata, Argentina
1160.47.54014 Boehringer Ingelheim Investigational Site
🇦🇷Mar del Plata, Argentina
1160.47.61001 Boehringer Ingelheim Investigational Site
🇦🇺Clayton, Victoria, Australia
1160.47.61004 Boehringer Ingelheim Investigational Site
🇦🇺Bedford Park, South Australia, Australia
1160.47.43001 Boehringer Ingelheim Investigational Site
🇦🇹Graz, Austria
1160.47.43002 Boehringer Ingelheim Investigational Site
🇦🇹Wien, Austria
1160.47.43004 Boehringer Ingelheim Investigational Site
🇦🇹Wien, Austria
1160.47.32001 Boehringer Ingelheim Investigational Site
🇧🇪Bruxelles, Belgium
1160.47.55007 Boehringer Ingelheim Investigational Site
🇧🇷Campinas - SP, Brazil
1160.47.55016 Boehringer Ingelheim Investigational Site
🇧🇷Rio de Janeiro - RJ, Brazil
1160.47.55014 Boehringer Ingelheim Investigational Site
🇧🇷Curitiba, Brazil
1160.47.55018 Boehringer Ingelheim Investigational Site
🇧🇷São Bernardo do Campo, Brazil
1160.47.35903 Boehringer Ingelheim Investigational Site
🇧🇬Sofia, Bulgaria
1160.47.35908 Boehringer Ingelheim Investigational Site
🇧🇬Rousse, Bulgaria
1160.47.55005 Boehringer Ingelheim Investigational Site
🇧🇷São José do Rio Preto, Brazil
1160.47.35910 Boehringer Ingelheim Investigational Site
🇧🇬Plovdiv, Bulgaria
1160.47.35901 Boehringer Ingelheim Investigational Site
🇧🇬Sofia, Bulgaria
1160.47.35904 Boehringer Ingelheim Investigational Site
🇧🇬Sofia, Bulgaria
1160.47.35906 Boehringer Ingelheim Investigational Site
🇧🇬Sofia, Bulgaria
1160.47.02006 Boehringer Ingelheim Investigational Site
🇨🇦Edmonton, Alberta, Canada
1160.47.35907 Boehringer Ingelheim Investigational Site
🇧🇬Sofia, Bulgaria
1160.47.35905 Boehringer Ingelheim Investigational Site
🇧🇬Varna, Bulgaria
1160.47.02013 Boehringer Ingelheim Investigational Site
🇨🇦Edmonton, Alberta, Canada
1160.47.02021 Boehringer Ingelheim Investigational Site
🇨🇦Victoria, British Columbia, Canada
1160.47.02002 Boehringer Ingelheim Investigational Site
🇨🇦Hamilton, Ontario, Canada
1160.47.02001 Boehringer Ingelheim Investigational Site
🇨🇦Halifax, Nova Scotia, Canada
1160.47.02004 Boehringer Ingelheim Investigational Site
🇨🇦Saint Johns, New Brunswick, Canada
1160.47.02005 Boehringer Ingelheim Investigational Site
🇨🇦Hamilton, Ontario, Canada
1160.47.02010 Boehringer Ingelheim Investigational Site
🇨🇦Hamilton, Ontario, Canada
1160.47.02022 Boehringer Ingelheim Investigational Site
🇨🇦Hamilton, Ontario, Canada
1160.47.02015 Boehringer Ingelheim Investigational Site
🇨🇦Ottawa, Ontario, Canada
1160.47.02008 Boehringer Ingelheim Investigational Site
🇨🇦Montreal, Quebec, Canada
1160.47.02009 Boehringer Ingelheim Investigational Site
🇨🇦Montreal, Quebec, Canada
1160.47.02014 Boehringer Ingelheim Investigational Site
🇨🇦Montreal, Quebec, Canada
1160.47.86001 Boehringer Ingelheim Investigational Site
🇨🇳Beijing, China
1160.47.02017 Boehringer Ingelheim Investigational Site
🇨🇦Montreal, Quebec, Canada
1160.47.86015 Boehringer Ingelheim Investigational Site
🇨🇳Beijing, China
1160.47.86003 Boehringer Ingelheim Investigational Site
🇨🇳Shanghai, China
1160.47.86005 Boehringer Ingelheim Investigational Site
🇨🇳Shanghai, China
1160.47.42001 Boehringer Ingelheim Investigational Site
🇨🇿Brno, Czech Republic
1160.47.42002 Boehringer Ingelheim Investigational Site
🇨🇿Hradec Kralove, Czech Republic
1160.47.42010 Boehringer Ingelheim Investigational Site
🇨🇿Usti nad Labem, Czech Republic
1160.47.42014 Boehringer Ingelheim Investigational Site
🇨🇿Tabor, Czech Republic
1160.47.45004 Boehringer Ingelheim Investigational Site
🇩🇰København NV, Denmark
1160.47.3301A Boehringer Ingelheim Investigational Site
🇫🇷Brest Cedex, France
1160.47.3302A Boehringer Ingelheim Investigational Site
🇫🇷Lorient, France
1160.47.49005 Boehringer Ingelheim Investigational Site
🇩🇪Mannheim, Germany
1160.47.49006 Boehringer Ingelheim Investigational Site
🇩🇪Mannheim, Germany
1160.47.49008 Boehringer Ingelheim Investigational Site
🇩🇪München, Germany
1160.47.36001 Boehringer Ingelheim Investigational Site
🇭🇺Budapest, Hungary
1160.47.30007 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1160.47.30009 Boehringer Ingelheim Investigational Site
🇬🇷Athens, Greece
1160.47.36002 Boehringer Ingelheim Investigational Site
🇭🇺Debrecen, Hungary
1160.47.36012 Boehringer Ingelheim Investigational Site
🇭🇺Gyula, Hungary
1160.47.36003 Boehringer Ingelheim Investigational Site
🇭🇺Pecs, Hungary
1160.47.91007 Boehringer Ingelheim Investigational Site
🇮🇳Mysore, India
1160.47.91015 Boehringer Ingelheim Investigational Site
🇮🇳Bangalore, India
1160.47.91001 Boehringer Ingelheim Investigational Site
🇮🇳Pune, India
1160.47.97207 Boehringer Ingelheim Investigational Site
🇮🇱Ashkelon, Israel
1160.47.97211 Boehringer Ingelheim Investigational Site
🇮🇱Haifa, Israel
1160.47.39009 Boehringer Ingelheim Investigational Site
🇮🇹Udine, Italy
1160.47.31007 Boehringer Ingelheim Investigational Site
🇳🇱Amsterdam, Netherlands
1160.47.64004 Boehringer Ingelheim Investigational Site
🇳🇿Christchurch, New Zealand
1160.47.48004 Boehringer Ingelheim Investigational Site
🇵🇱Kielce, Poland
1160.47.47005 Boehringer Ingelheim Investigational Site
🇳🇴Trondheim, Norway
1160.47.48005 Boehringer Ingelheim Investigational Site
🇵🇱Krakow, Poland
1160.47.48003 Boehringer Ingelheim Investigational Site
🇵🇱Poznan, Poland
1160.47.35101 Boehringer Ingelheim Investigational Site
🇵🇹Lisboa, Portugal
1160.47.48006 Boehringer Ingelheim Investigational Site
🇵🇱Warsaw, Poland
1160.47.35109 Boehringer Ingelheim Investigational Site
🇵🇹Coimbra, Portugal
1160.47.07022 Boehringer Ingelheim Investigational Site
🇷🇺Belgorod, Russian Federation
1160.47.07011 Boehringer Ingelheim Investigational Site
🇷🇺Chelyabinsk, Russian Federation
1160.47.35105 Boehringer Ingelheim Investigational Site
🇵🇹Lisboa, Portugal
1160.47.07007 Boehringer Ingelheim Investigational Site
🇷🇺Ekaterinburg, Russian Federation
1160.47.07016 Boehringer Ingelheim Investigational Site
🇷🇺Krasnodar, Russian Federation
1160.47.07004 Boehringer Ingelheim Investigational Site
🇷🇺Kursk, Russian Federation
1160.47.07018 Boehringer Ingelheim Investigational Site
🇷🇺Pskov, Russian Federation
1160.47.07020 Boehringer Ingelheim Investigational Site
🇷🇺Omsk, Russian Federation
1160.47.07009 Boehringer Ingelheim Investigational Site
🇷🇺Rostov-na-Donu, Russian Federation
1160.47.07025 Boehringer Ingelheim Investigational Site
🇷🇺Rostov-na-Donu, Russian Federation
1160.47.07023 Boehringer Ingelheim Investigational Site
🇷🇺Rostov-na-Donu, Russian Federation
1160.47.07001 Boehringer Ingelheim Investigational Site
🇷🇺St. Petersburg, Russian Federation
1160.47.07019 Boehringer Ingelheim Investigational Site
🇷🇺Tyumen, Russian Federation
1160.47.07002 Boehringer Ingelheim Investigational Site
🇷🇺St. Petersburg, Russian Federation
1160.47.07017 Boehringer Ingelheim Investigational Site
🇷🇺St. Petersburg, Russian Federation
1160.47.07014 Boehringer Ingelheim Investigational Site
🇷🇺Ufa, Russian Federation
1160.47.07006 Boehringer Ingelheim Investigational Site
🇷🇺Yaroslavl, Russian Federation
1160.47.07005 Boehringer Ingelheim Investigational Site
🇷🇺Yaroslavl, Russian Federation
1160.47.42107 Boehringer Ingelheim Investigational Site
🇸🇰Banska Bystrica, Slovakia
1160.47.27003 Boehringer Ingelheim Investigational Site
🇿🇦Randburg, South Africa
1160.47.34002 Boehringer Ingelheim Investigational Site
🇪🇸Barcelona, Spain
1160.47.46006 Boehringer Ingelheim Investigational Site
🇸🇪Jönköping, Sweden
1160.47.46001 Boehringer Ingelheim Investigational Site
🇸🇪Stockholm, Sweden
1160.47.34004 Boehringer Ingelheim Investigational Site
🇪🇸Santander, Spain
1160.47.46002 Boehringer Ingelheim Investigational Site
🇸🇪Göteborg, Sweden
1160.47.90005 Boehringer Ingelheim Investigational Site
🇹🇷Ankara, Turkey
1160.47.90007 Boehringer Ingelheim Investigational Site
🇹🇷Istanbul, Turkey
1160.47.44009 Boehringer Ingelheim Investigational Site
🇬🇧London, United Kingdom
1160.47.44011 Boehringer Ingelheim Investigational Site
🇬🇧London, United Kingdom
1160.47.44005 Boehringer Ingelheim Investigational Site
🇬🇧Headington, Oxford, United Kingdom
1160.47.44012 Boehringer Ingelheim Investigational Site
🇬🇧Sheffield, United Kingdom
1160.47.01039 Boehringer Ingelheim Investigational Site
🇺🇸Winston-Salem, North Carolina, United States
1160.47.61003 Boehringer Ingelheim Investigational Site
🇦🇺Box Hill, Victoria, Australia
1160.47.36004 Boehringer Ingelheim Investigational Site
🇭🇺Miskolc, Hungary
1160.47.42005 Boehringer Ingelheim Investigational Site
🇨🇿Ostrava-Vitkovice, Czech Republic
1160.47.91011 Boehringer Ingelheim Investigational Site
🇮🇳Bangalore, India
1160.47.91009 Boehringer Ingelheim Investigational Site
🇮🇳Madurai, India
1160.47.42007 Boehringer Ingelheim Investigational Site
🇨🇿Zlin, Czech Republic
1160.47.91004 Boehringer Ingelheim Investigational Site
🇮🇳Vadodara, India
1160.47.52036 Boehringer Ingelheim Investigational Site
🇲🇽Chihuahua, Mexico
1160.47.52027 Boehringer Ingelheim Investigational Site
🇲🇽Monterrey, Mexico
1160.47.52034 Boehringer Ingelheim Investigational Site
🇲🇽San Luis Potosí, Mexico
1160.47.35102 Boehringer Ingelheim Investigational Site
🇵🇹Lisboa, Portugal
1160.47.91003 Boehringer Ingelheim Investigational Site
🇮🇳New Delhi, India
1160.47.91010 Boehringer Ingelheim Investigational Site
🇮🇳New Delhi, India
1160.47.52039 Boehringer Ingelheim Investigational Site
🇲🇽Culiacan, Mexico
1160.47.47001 Boehringer Ingelheim Investigational Site
🇳🇴Oslo, Norway
1160.47.47004 Boehringer Ingelheim Investigational Site
🇳🇴Oslo, Norway
1160.47.47003 Boehringer Ingelheim Investigational Site
🇳🇴Rud, Norway
1160.47.42104 Boehringer Ingelheim Investigational Site
🇸🇰Zilina, Slovakia
1160.47.43003 Boehringer Ingelheim Investigational Site
🇦🇹Innsbruck, Austria
1160.47.91008 Boehringer Ingelheim Investigational Site
🇮🇳Pune, India
1160.47.91014 Boehringer Ingelheim Investigational Site
🇮🇳Trivandrum, India